These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30170622)

  • 21. Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
    Tsiogka A; Jansky GL; Bauer JW; Koelblinger P
    Melanoma Res; 2017 Oct; 27(5):524-525. PubMed ID: 28858175
    [No Abstract]   [Full Text] [Related]  

  • 22. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
    Patel AS; Snook RJ; Sehdev A
    Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
    Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    Kelly Wu W; Broman KK; Brownie ER; Kauffmann RM
    J Immunother; 2017 Jun; 40(5):196-199. PubMed ID: 28452849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab.
    Choe JH; Andonian BJ; Kim GJ; Salama AK
    Immunotherapy; 2016 Oct; 8(10):1163-7. PubMed ID: 27605066
    [No Abstract]   [Full Text] [Related]  

  • 28. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab.
    Choi JS; Chen M; McQuade JL; Appelbaum E; Gidley PW; Nader ME
    Head Neck; 2020 Nov; 42(11):E35-E42. PubMed ID: 32888241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
    de Moel EC; Rozeman EA; Kapiteijn EH; Verdegaal EME; Grummels A; Bakker JA; Huizinga TWJ; Haanen JB; Toes REM; van der Woude D
    Cancer Immunol Res; 2019 Jan; 7(1):6-11. PubMed ID: 30425107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome.
    Patel RJ; Liu MA; Amaraneni A; Sindhu SK
    BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29237657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
    Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
    J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
    Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
    J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy.
    Eryılmaz MK; Mutlu H; Salim DK; Musri FY; Tural D; Başsorgun I; Coşkun HŞ
    J Oncol Pharm Pract; 2016 Jun; 22(3):533-6. PubMed ID: 25694346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
    Gambichler T; Stockfleth E; Susok L
    J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab-associated halo-like inflammatory reactions around nevi during therapy for metastatic melanoma.
    Alniemi DT; Fischer A; Greene LA; Pierson JC
    Dermatol Online J; 2018 Jul; 24(7):. PubMed ID: 30261564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
    Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
    J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
    Mangana J; Dimitriou F; Braun R; Ludwig S; Dummer R; Barysch MJ
    Melanoma Res; 2019 Dec; 29(6):648-654. PubMed ID: 30870270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.